Tag: AV access

Merit Medical Systems has announced positive results from a prospective, observational, first-in-human study to evaluate the safety and effectiveness of Wrapsody—a self-expanding, cell-impermeable endoprosthesis...

Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...

 A trio of vascular experts including Raphaël Coscas (Paris, France), Alexandros Mallios (Paris, France) and Kate Steiner (Stevenage, UK) discuss the key findings of...

Mermaid Medical Group recently announced US commercial availability of the D-Clot HD rotational thrombectomy system. As of 12 January, the company reports 25 successful...

NOTE: This video is ONLY available to watch in selected countries and geographies Robert Lookstein (New York, USA; principal investigator) and Andrew Holden (Auckland,...

 Throwback to the 2019 Society of Interventional Radiology annual scientific meeting when Interventional News interviewed Bart Dolmatch (Mountain View, USA) on the early results of the AVeNEW trial - the first Level One trial dedicated solely to assess the safety...

NOTE: This video is ONLY available to watch in selected countries and geographies Andrew Holden (Auckland, New Zealand), Alexandros Mallios (Paris, France), Robert Lookstein (New...

NOTE: This video is ONLY available to watch in selected countries and geographies  The one-year IN.PACT AV trial results, first presented at LINC 2020 (28–31 January, Leipzig,...

NOTE: This video is ONLY available to watch in selected countries and geographies   Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...

There in an increasing physician interest in exploring the role of drug-coated balloons in arteriovenous (AV) access. At the Leipzig Interventional Course (LINC; 30...

The US FDA has approved the investigational device exemption (IDE) study to evaluate the safety and efficacy of IN.PACT AV access drug-coated balloon as...

Scott Trerotola presented the first release of eight-month data from the Lutonix AV IDE trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig,...